XML 64 R49.htm IDEA: XBRL DOCUMENT v3.24.2
Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Principal Changes in Scope of Consolidation (Details)
$ / shares in Units, € in Millions, $ in Millions
6 Months Ended 12 Months Ended
Jun. 30, 2024
EUR (€)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
EUR (€)
Dec. 31, 2023
EUR (€)
May 30, 2024
EUR (€)
May 30, 2024
USD ($)
$ / shares
Disclosure of detailed information about business combination [line items]            
Net cash flow on acquisition | € [1] € 1,885   € 2,465 € 3,870    
Name of acquiree Inhibrx, Inc Inhibrx, Inc        
Assets Acquisition            
Disclosure of detailed information about business combination [line items]            
Consideration transferred, acquisition-date fair value           $ 2,035
Identifiable intangible assets recognised as of acquisition date           $ 1,908
Net cash flow on acquisition   $ 2,035        
Assets Acquisition Nominal Value | €         € 300  
Assets Acquisition, Purchase Price Per Share | $ / shares           $ 5.00
[1] For the six months ended June 30, 2024, this line item includes the net cash outflow arising from the acquisition of Inhibrx, Inc. (see Note B.1.1.). For the six months ended June 30, 2023, this line includes the net cash outflow arising from the acquisition of Provention Bio Inc. For the year ended December 31, 2023, it includes the net cash outflow arising from the acquisitions of Provention Bio Inc and QRIB.